LIB Therapeutics
LIB Therapeutics is a privately held, commercial-stage biopharmaceutical company dedicated to bringing novel, highly effective, and safe therapies to help the millions of people with cardiovascular disease and familial hypercholesterolemia finally achieve their LDL-C goals.
Lerodalcibep
Lerodalcibep is a novel, third-generation PCSK9 inhibitor designed to overcome the limitations of current low density lipoprotein-cholesterol (LDL-C) lowering treatments, including statins and ezetimibe, to achieve the lower LDL-C targets in recently updated national and international guidelines to treat and prevent cardiovascular disease (CVD). Lerodalcibep is a convenient, single, small-volume, once-monthly dose with long-ambient stability. Combined with sustained LDL-C reductions demonstrated in clinical trials, lerodalcibep expands treatment options for the millions of patients around the world with atherosclerotic cardiovascular disease (ASCVD), and those at very high and high risk for ASCVD, including the 30 million individuals with more severe inherited high cholesterol called familial hypercholesterolemia (FH).
Approach
We developed lerodalcibep, a novel, third-generation, PCSK9 inhibitor as a convenient, single, once-monthly subcutaneous dose for patient convenience.
Team
LIB Therapeutics was founded in 2015 by an experienced team that recognized a long-standing challenge in lipid management: While effective therapies existed, significant unmet need remained, underscoring the importance of developing lerodalcibep to help more patients achieve and maintain their LDL-C goals long term.
Patients
Cardiovascular disease is the #1 global cause of death. More than 100M patients worldwide in 2020 had clinically significant ASCVD that required treatment. Clinically significant ASCVD patient population will increase to 137M patients by 2030. We aim to help patients achieve and maintain their LDL-C goals.
